

# NEO: Olaparib Window of Opportunity


- **Primary:** To measure the biological effect of olaparib in terms of PARP inhibition

- **Secondary:**

- Response rate of olaparib in neo-adjuvant setting
- PFS1 and PFS2
- Pharmacodynamic changes: HRD mutations/ gene expression
- ctDNA as blood biomarkers

- **Exploratory:**


- Heterogeneity
- Clonal evolution



**17 patients enrolled**

## PMHC

# EVOLVE: A proof of concept trial of combination of Olaparib + Cediranib



Platinum SENSITIVE disease	11/11 pts
Platinum RESISTANT disease	10/10 pts
Prior PARPi progression, treated with further chemo	11/11 pts

**Enrollment completed**


ctDNA profiling



RNA Sequencing



IHC



Somatic DNA profiling



**Analysis on-going**